(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Gossamer Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast GOSS's revenue for 2025 to be $3,090,476,825, with the lowest GOSS revenue forecast at $3,090,476,825, and the highest GOSS revenue forecast at $3,090,476,825. On average, 3 Wall Street analysts forecast GOSS's revenue for 2026 to be $16,143,342,557, with the lowest GOSS revenue forecast at $6,226,070,100, and the highest GOSS revenue forecast at $34,647,177,778.
In 2027, GOSS is forecast to generate $36,843,446,564 in revenue, with the lowest revenue forecast at $7,259,236,805 and the highest revenue forecast at $69,028,168,500.